The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

Published:2024-02-18 Issue:4 Volume:19 Page:377-391
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Strassl Irene¹²,Podar Klaus³⁴

Affiliation:

1. Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz Hospital, Linz, Austria

2. Medical Faculty, Johannes Kepler University Linz, Linz, Austria

3. Department of Internal Medicine II, University Hospital Krems, Austria

4. Division of Molecular Oncology and Hematology, Department of General and Translational Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2024.2319672

Reference140 articles.

1. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

5. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties;International Journal of Molecular Sciences;2024-05-22